Amneal Pharmaceuticals(AMRX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS ‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, October 30, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2025. "Amneal delivered another strong quarter and updated o ...